Intralesional collagenase such as Xiaflex (ILX) has become a standard treatment for Peyronie’s disease (PD). Many robust studies have demonstrated its clear efficacy in the treatment algorithm.
To examine predictors of the patient decision to pursue ILX in PD patients.